Please login to the form below

Not currently logged in


This page shows the latest elotuzumab news and features for those working in and with pharma, biotech and healthcare.

Sanofi's Darzalex rival scores in myeloma trial

Sanofi's Darzalex rival scores in myeloma trial

Another rival is Bristol-Myers Squibb and AbbVie’s Empliciti (elotuzumab), which targets SLAMF7 rather than CD38 which was approved for the relapsed/refractory patient population in 2015 in combination with

Latest news

More from news
Approximately 6 fully matching, plus 22 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Fendix is the only NHS digital media network and it provides organisations, such as pharma, with unrivalled digital access to...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...